What NICE says about semaglutide for weight loss

What exactly does the NICE guidance say semaglutide can be used for?

The NICE appraisal covers semaglutide 2.4mg (Wegovy) as a treatment for weight management, sitting alongside a reduced-calorie diet and increased physical activity. The NICE recommendation (TA875) specifies that it should be used within a specialist weight management service — one that provides multidisciplinary input — and for no longer than two years in any individual patient.

The NHS BMI threshold under TA875 is 35 kg/m² or above, with at least one weight-related comorbidity such as high blood pressure, type 2 diabetes or obstructive sleep apnoea. People from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds typically qualify at thresholds 2.5 kg/m² lower, in line with broader NHS guidance on ethnicity-adjusted BMI. NICE also sets a review point: if someone has not lost at least 5% of their starting weight after six months on the maintenance dose, continuing the medicine should be reconsidered.

The semaglutide licence itself is actually broader than the NICE NHS recommendation. The medicine is licensed for adults with a BMI of 30 or above, or 27 or above if a weight-related condition is present. That gap between licensed use and NICE's NHS criteria is why some people who are clinically eligible for private treatment do not yet qualify through the NHS pathway. For a fuller breakdown of how the appraisal maps to real-world access, our semaglutide for weight loss overview covers the detail.

What trial evidence did NICE rely on when making its recommendation?

The appraisal drew heavily on the STEP trial programme, particularly STEP 1, which followed adults with obesity over 68 weeks. Participants taking semaglutide 2.4mg alongside lifestyle support lost an average of around 15% of body weight compared with roughly 2.4% in the placebo group. That study was published in the New England Journal of Medicine and formed the clinical backbone of the appraisal committee's assessment of clinical and cost-effectiveness.

Since TA875 was published, Novo Nordisk has secured MHRA approval for a higher 7.2mg maintenance dose of Wegovy, with trial data reporting average weight loss of around 20.7% over 72 weeks. The single-dose 7.2mg pen was approved on 14 April 2026. NICE has not updated TA875 to formally address the higher dose yet, so it sits outside the appraisal's scope for now. If you are curious about how semaglutide's results compare across doses and against other treatments, our Wegovy results page sets out the evidence cleanly.

It is worth being clear about what these figures represent: averages from clinical trials in defined populations, not a guarantee for any individual. Biology, starting weight, adherence and lifestyle all affect outcome, and if you are wondering how to build muscle on Wegovy while losing weight, a prescriber can help you think through what is realistic in your own situation.

Does the NICE guidance cover private prescriptions too?

NICE appraisals govern what the NHS in England will fund; they do not restrict private prescribing. A GPhC-registered independent prescriber working in a private setting can prescribe semaglutide to any patient who meets the licensed criteria and for whom it is clinically appropriate, without being bound by the two-year limit or the specialist-service requirement that TA875 sets for NHS use.

This matters practically. NHS waiting lists for specialist weight management services can be long, and the phased NHS rollout means many people who qualify medically may wait months or years for access. Private treatment through a regulated pharmacy is the alternative for those who would rather not wait or who sit outside the current NHS criteria. Some people order on a Monday morning; others time it around a payday or before a holiday when motivation is high. Whenever you start, what matters is that treatment comes through a pharmacy you can verify on the GPhC register.

One clarification that comes up regularly: Ozempic is semaglutide but licensed only for type 2 diabetes, not weight management. Our semaglutide overview explains the distinction properly, including why prescribing Ozempic for weight loss sits outside its UK licence. For a look at how Wegovy's costs compare with what a private prescription typically includes, our Wegovy cost page lays it out without the marketing noise.

At nume, every consultation is read by a GPhC-registered independent prescriber on the same day, someone who knows the TA875 framework and can assess where you sit relative to both the licensed criteria and the NHS thresholds. If semaglutide is right for you, they will say so. If something else fits better, they will tell you that instead. Start your free consultation to find out where you stand.